Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema
- 65 Downloads
We would like to address several challenges that have arisen from the study by Campos et al. .
There was a selection bias attributable to inclusion in the study of patients with different forms of non-proliferative diabetic retinopathy (mild/moderate/severe) diagnosed with recent diabetic macular edema (DME). It should be noted that 50.8% of the eyes included had a past history of macular photocoagulation (treatment-non-naïve patients). In addition, the treatments administered to patients were different, namely 113 eyes were treated with a loading dose of 0.5 mg ranibizumab (Lucentis; Genentech Inc., South San Francisco, CA, USA), 13 eyes were treated with a loading dose of 2 mg aflibercept (Eylea; Regeneron Pharmaceutical Inc., Tarrytown, NY, USA), and 18 were switched from ranibizumab to aflibercept. Importantly, eyes that developed proliferative diabetic retinopathy and needed panretinal photocoagulation, eyes that were rescued with focal/grid laser, and eyes that...
Both authors (D.C and M.C) were involved in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review, or approval of the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The authors have full control over the primary data and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.
- 1.Campos A, Campos EJ, do Carmo A, Patricio M, Castro de Sousa JP, Ambrosio AF, Silva RC (2018) Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. https://doi.org/10.1007/s00417-018-4072-z Published online: July 23, 2018
- 5.Călugăru D, Călugăru M (2018) Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment. Am J Ophthalmol 256:1035–1037Google Scholar